Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Autoimmune Partnering Directory 2012-2018: Deal Trends, Players and Financials - ResearchAndMarkets.com

Research and Markets
Posted on: 22 Mar 18

The "Global Autoimmune Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Global Autoimmune Partnering 2012 to 2018 provides the full collection of Autoimmune disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.

  • Trends in Autoimmune partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Autoimmune partnering agreement structure
  • Autoimmune partnering contract documents
  • Top Autoimmune deals by value
  • Most active Autoimmune dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Autoimmune disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Autoimmune deals.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Autoimmune technologies and products.

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Autoimmune dealmaking

2.1. Introduction

2.2. Autoimmune partnering over the years

2.3. Autoimmune partnering by deal type

2.4. Autoimmune partnering by industry sector

2.5. Autoimmune partnering by stage of development

2.6. Autoimmune partnering by technology type

2.7. Autoimmune partnering by therapeutic indication

Chapter 3 - Financial deal terms for Autoimmune partnering

3.1. Introduction

3.2. Disclosed financials terms for Autoimmune partnering

3.3. Autoimmune partnering headline values

3.4. Autoimmune deal upfront payments

3.5. Autoimmune deal milestone payments

3.6. Autoimmune royalty rates

Chapter 4 - Leading Autoimmune deals and dealmakers

4.1. Introduction

4.2. Most active in Autoimmune partnering

4.3. List of most active dealmakers in Autoimmune

4.4. Top Autoimmune deals by value

Chapter 5 - Autoimmune contract document directory

5.1. Introduction

5.2. Autoimmune partnering deals where contract document available

Chapter 6 - Autoimmune dealmaking by therapeutic target

6.1. Introduction

6.2. Deals by Autoimmune therapeutic target

For more information about this report visit https://www.researchandmarkets.com/research/jrvbkk/global_autoimmune?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20180322005622/en/

Business Wire
www.businesswire.com

Last updated on: 22/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.